Karger Kompass Onkologie最新文献_第3页

Die CML geht voran 已经开始了

Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000502534

S. Saußele

引用次数: 0

Aggressives Prostatakarzinom: Methoden zur frühzeitigen Detektion dringend gesucht 积极前列腺癌早期侦察技术

Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000502071

H. Kübler

{"title":"Aggressives Prostatakarzinom: Methoden zur frühzeitigen Detektion dringend gesucht","authors":"H. Kübler","doi":"10.1159/000502071","DOIUrl":"https://doi.org/10.1159/000502071","url":null,"abstract":"Background: Aggressive variant transformation in metastatic castration-resistant prostate cancer (mCRPC) represents an under-recognized phenomenon. There is an urgent need for non-invasive biomarkers to detect these variants and identify treatment alternatives. Methods: A prospective observational pilot study in mCRPC patients receiving treatment with cabazitaxel (CAB) was conducted. Neuromediators were sequentially evaluated and their impact on disease endpoints calculated. Targeted next-generation sequencing (NGS) of cell-free DNA (cfDNA) was also performed in a highly pretreated subset of patients. Results: 23 patients were included. Estimated effects indicate that neuron-specific enolase (NSE) levels at baseline may be correlated with overall survival (NSE unit 18.3 ng/ml: HR1.262 (95% confidence interval (CI) 0.985-1.616)) and that chromogranin A (CGA) may be correlated with progression-free survival (CGA unit 98.1 ng/ml: HR1.341 (95% CI 1.011-1.778)). cfDNA analysis revealed mutations annotated in prostate cancer (PCA) and small cell cancers (SCC). 1 patient showed elevated neuromediators along with annotated mutations in PCA and SCC, potentially indicating aggressive variant cancer. In 3 patients KIT mutations (e.g. pM541L, pV654A) known to be tissue-based biomarkers with level 1 evidence for the treatment with imatinib and sunitinib were found. Conclusions: Sequential analysis of neuromediators and targeted NGS of cfDNA provide insight for the estimation of tumor heterogeneity under therapy with CAB.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122473920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Krukenberg-Tumoren: Wichtige klinische Fragen sind bisher nicht beantwortet 克鲁肯堡肿瘤:重要的临床问题还没有得到回答

Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000501890

K. Homayounfar

{"title":"Krukenberg-Tumoren: Wichtige klinische Fragen sind bisher nicht beantwortet","authors":"K. Homayounfar","doi":"10.1159/000501890","DOIUrl":"https://doi.org/10.1159/000501890","url":null,"abstract":"Background: The treatment of metachronous Krukenberg tumor (mKT) from gastric cancer remains unexplored. We performed a literature review to evaluate whether or not surgical treatment improves survival. Methods: A systematic review according to PRISMA guidelines was performed. Studies reporting on patients who underwent surgical treatment for mKT from gastric cancer were selected. Metachronous disease was divided as follows: confined to the ovaries, confined to the pelvis, or beyond the pelvis. Outcomes evaluated included overall survival (OS), progression-free survival (PFS), resection rate (R0), and factors predicting survival. Results: 13 retrospective reports fulfilled the selection criteria (512 patients). Most of the patients presented at a premenopausal age. The median presentation interval from gastrectomy ranged from 16 to 21.4 months. Median OS ranged between 9 and 36 months. 1-year OS ranged between 52.5 and 59%, and 3-years OS between 9.8 and 36.5%. Resection margin, peritoneal seeding, and chemotherapy regimen and cycles influenced survival. Conclusion: Surgical treatment and adjuvant chemotherapy in patients with mKT from gastric cancer seems to be associated with improved survival and is justified especially in young patients. Disease location and R0 resection should be considered when selecting patients.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"94 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127212563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Melanoma in situ/Lentigo maligna: Wo und bei wem darauf geachtet werden muss Melanoma, siu /Lentigo malika

Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000502163

J. Maschke

{"title":"Melanoma in situ/Lentigo maligna: Wo und bei wem darauf geachtet werden muss","authors":"J. Maschke","doi":"10.1159/000502163","DOIUrl":"https://doi.org/10.1159/000502163","url":null,"abstract":"Introduction: Lentigo maligna (LM) is a rare form of in situ melanoma, frequently seen as a large patch in elderly patients. The aim of this study was to assess clinical and dermoscopic features of LM. Material and Methods: A retrospective study of LM patients presenting to our center between July 2007 and July 2017 was performed. Demographic data, anatomical location, laterality, diameter, Clark level, Breslow stage, ‘ABCD' signs and dermoscopic features were registered. Facial versus extrafacial LM were compared. Results: We found 21 LM, of which 12 had an extrafacial location and 9 a facial location. Half of the extrafacial lesions were located on an upper limb. The median age at diagnosis was 63 years (ranging from 38 to 84 years). Most LM cases were female (16/21) with phototype II (13/21). More than half of the patients (11/21) had a history of a skin neoplasm or actinic keratosis. The median diameter found was 6 mm (interquartile range = 4.5 mm), ranging from 1 to 15 mm. Five lesions were invasive (median Breslow depth of 0.2 mm), and 4 of them were extrafacial. Discussion: In this study LM was more frequently found in an extrafacial location and as a small patch with a 6-mm diameter medium. The epidemiology of LM/LM melanoma might be changing. Full body examination and dermoscopy are of the utmost importance for the diagnosis. Dermatologists should be aware and search for small lesions outside the face and neck, particularly in middle-aged female patients with photo-damaged skin.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"82 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132361164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nicht-kleinzelliges Lungenkarzinom: Welche Rolle microRNA in der Behandlung spielt 非非同小可的肺结核决定了microRNA在治疗中所起的作用

Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000502104

N. Reinmuth

{"title":"Nicht-kleinzelliges Lungenkarzinom: Welche Rolle microRNA in der Behandlung spielt","authors":"N. Reinmuth","doi":"10.1159/000502104","DOIUrl":"https://doi.org/10.1159/000502104","url":null,"abstract":"Background: The role of microRNA-133a (miR-133a) in non-small cell lung cancers (NSCLCs) is controversial. Thus, we conducted a comprehensive study based on meta-analysis and The Cancer Genome Atlas (TCGA) database. Methods: Publications were searched in both English and Chinese databases, and meta-analysis was performed using Stata 12.0. The clinical value of miR-133a in NSCLC was investigated by collecting and calculating data from the TCGA database, and the statistical analysis was performed in R 3.5.0. Results: 5 studies with 364 cases were included in this meta-analysis. The combined pooled result showed that high expression of miR-133a was associated with a favorable survival outcome in NSCLC patients (hazard ratio 0.561, 95% confidence interval 0.396-0.794, p = 0.001). Meanwhile, a total of 984 NSCLC patients were extracted from the TCGA database. Results showed an area under the ROC curve value for miR-133a-3p of 0.902, and the expression of miR-133a-3p was linked with clinicopathologic parameters of NSCLC (p < 0.05), including sex, age, social status, and lymph node metastasis. Conclusion: Our study indicated that miR-133a might act as a tumor suppressor and be a valuable independent prognostic and diagnostic biomarker for NSCLC, and NSCLC patients with high expression of miR-133 might have a better prognosis.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131399941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ansprechen auf Imatinib ist bei chronischer myeloischer Leukämie mit BCR-ABL1-Transkriptvariante e13a2 schlechter als bei Transkriptvariante e14a2 对伊壁鸠鲁类白血病的慢性髓细胞性白血病比转录类e14a2更不利

Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000501948

Graeme Greenfield, R. Mcmullan, N. Robson, Julie McGimpsey, Mark Catherwood, Mary Frances McMullin

{"title":"Ansprechen auf Imatinib ist bei chronischer myeloischer Leukämie mit BCR-ABL1-Transkriptvariante e13a2 schlechter als bei Transkriptvariante e14a2","authors":"Graeme Greenfield, R. Mcmullan, N. Robson, Julie McGimpsey, Mark Catherwood, Mary Frances McMullin","doi":"10.1159/000501948","DOIUrl":"https://doi.org/10.1159/000501948","url":null,"abstract":"Hintergrund: Das BCR-ABL1-Fusionsgen, das der Pathogenese der CML zugrunde liegt, kann aus einer Reihe verschiedener Bruchstellen entstehen. Die häufigsten Varianten sind die Transkripte e13a2 und e14a2, die durch Bruchstellen im Bereich von Exon 13 bzw. Exon 14 des BCR-Gens entstehen. Methoden: In einer retrospektiven Analyse werteten wir lokale Labordatenbanken und elektronische Patientenakten von 69 CML-Patienten mit e13a2- oder e14a2-Transkriptvariante aus, die wir in unserer regionalen Population identifiziert hatten. Ergebnisse: Die e13a2-Gruppe war im Durchschnitt signifikant jünger (45,0 Jahre vs. 54,5 Jahre), ihre durchschnittliche Leukozytenzahl war höher (189,8 × 109/l vs. 92,40 × 109/l) und die Thrombozytenzahl niedriger (308 × 109/l vs. 644 × 109/l) als in der e14a2-Gruppe, was darauf hindeutet, dass es sich um unterschiedliche biologische Entitäten handelt. Über einen durchschnittlichen Nachbeobachtungszeitraum von 33,8 Monaten (e13a2) bzw. 27,2 Monaten (e14a2) beobachteten wir ein schlechteres molekulares Ansprechen auf Imatinib in der e13a2-Gruppe. Eine signifikant geringere Anzahl von Patienten im e13a2-Arm erfüllte die Kriterien des European Leukemia Net für ein optimales Ansprechen nach 12-monatiger Therapiedauer (17,64% vs. 50,0%), und es dauerte länger, bis sie ein umfassendes molekulares Ansprechen (MR4 oder MR4.5) erreichten. Schlussfolgerung: In den Populationen unserer Region zeigen Patienten mit einer e13a2-Transkriptvariante ein schlechteres molekulares Ansprechen auf Imatinib.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"100 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121476576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stammzelltransplantation: Therapieentscheidung wird häufig nicht rechtzeitig getroffen 干细胞移植:许多人没有及时接受治疗

Karger Kompass Onkologie Pub Date : 2019-09-01 DOI: 10.1159/000502160

S. Saußele

{"title":"Stammzelltransplantation: Therapieentscheidung wird häufig nicht rechtzeitig getroffen","authors":"S. Saußele","doi":"10.1159/000502160","DOIUrl":"https://doi.org/10.1159/000502160","url":null,"abstract":"Two decades after the introduction of tyrosine kinase inhibitors (TKI), a sizeable portion of patients with chronic myeloid leukemia (CML) in chronic phase (CP) still undergo allogeneic stem cell transplantation (allo-HSCT). We investigated the indications for allo-HSCT, clinical outcome, management of relapse, and post-transplant TKI treatment in a population-based setting using the Swedish CML registry. Of 118 CML patients transplanted between 2002 and 2017, 56 (47.4%) received allo-HSCT in first CP, among whom TKI resistance was the most common transplant indication (62.5%). For patients diagnosed with CML in CP at <65 years of age, the cumulative probability of undergoing allo-HSCT within 5 years was 9.7%. Overall 5-year survival was 96.2%, 70.1% and 36.9% when transplanted in first CP, second or later CP, and in accelerated phase or blast crisis, respectively. Risk factors for relapse were EBMT score >2 and reduced intensity conditioning, and for death, CP > 2 at time point of allo-HSCT only. Non-relapse mortality for patients transplanted in CP was 11.6%. Our data indicate that allo-HSCT still constitutes a reasonable therapeutic option for patients with CML in first CP, especially those resistant to TKI treatment, providing high long-term survival and low non-relapse mortality.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126680171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frühe Integration von Palliativversorgung - was wirklich diskutiert werden sollte 早期整合镇静护理——这应该好好讨论

Karger Kompass Onkologie Pub Date : 2019-05-01 DOI: 10.1159/000499358

K. Oechsle

{"title":"Frühe Integration von Palliativversorgung - was wirklich diskutiert werden sollte","authors":"K. Oechsle","doi":"10.1159/000499358","DOIUrl":"https://doi.org/10.1159/000499358","url":null,"abstract":"By definition, palliative care (PC) is applicable already in early stages of incurable and life-threatening diseases, in conjunction with therapies that are intended to prolong life, such as for example chemo- or radiotherapy. Many patients suffer from distressing symptoms or problems in early phases of such illness. Therefore, it is not a question of «if» PC should be integrated early into oncology, but «how». General PC is defined as an approach that should be delivered by healthcare professionals regardless of their discipline. This is often referred to as «general» or «primary» PC. For this, routine symptom assessment, expertise concerning basic symptom management and communication skills are basic requirements. Communication skills include the willingness to engage in discussions concerning patients' fears, worries and end-of-life issues without the fear of destroying hope. Specialist PC is provided by specialist teams regardless of the patients' disease, be it cancer or non-cancer. Such teams should be integrated in the care of PC patients depending on the availability of these services and the patients' needs. Key messages: «Early PC» must not be used synonymously with «early specialist PC» because much of the PC is delivered as basic oncology PC. For the integration of specialist PC, the identification of triggers is warranted in different institutions to facilitate a meaningful and effective cooperation. Such cooperations should be based on patients' needs, but must also account for questions of availability and resources.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131050462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Langzeittoxizität der adjuvanten Mammakarzinomtherapie ist nicht zu unterschätzen 不可低估乳癌伴随物的长期毒性

Karger Kompass Onkologie Pub Date : 2019-05-01 DOI: 10.1159/000499888

M. Banys-Paluchowski, T. Fehm

{"title":"Langzeittoxizität der adjuvanten Mammakarzinomtherapie ist nicht zu unterschätzen","authors":"M. Banys-Paluchowski, T. Fehm","doi":"10.1159/000499888","DOIUrl":"https://doi.org/10.1159/000499888","url":null,"abstract":"Background: Chronic treatment sequelae may substantially reduce the long-term quality of life in breast cancer survivors. Methods: We report a comprehensive Web-based survey on the presence of long-term side effects of adjuvant anti-breast cancer therapy in 1,506 patients who had been diagnosed with primary breast cancer at least 1 year before. Results: Fatigue, depression, depressive mood, concentration deficit, pain, changes of mucosa and skin appendages, as well as symptoms of peripheral neuropathy were the most prevalent reported complaints. Chemotherapies - taxane-based regimens in particular - were associated with in-creased rates of long-term symptoms, including persistent peripheral neuropathy. Overall, the data show a substantial prevalence of a wide variety of potentially treatment-associated symptoms over a protracted time frame after the diagnosis of breast cancer. The burden of symptoms was high for fatigue, depression, sleep disturbances, pain, and peripheral neuropathic symptoms. Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.","PeriodicalId":351794,"journal":{"name":"Karger Kompass Onkologie","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127628998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Veranstaltungskalender 酒店

Karger Kompass Onkologie Pub Date : 2019-05-01 DOI: 10.1159/000500508

引用次数: 0